BioLife becomes the leading supplier of pre-formulated cord blood stem cell freeze media products

BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced that it has become the leading supplier of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells, a key segment of the Company's strategic biobanking market. BioLife Solutions, which will be exhibiting at the 9th Annual International Umbilical Cord Blood Transplantation Symposium June 23-25 in San Francisco, also announced that it has captured a significant share of this market through its expanding relationships with direct and indirect customers such as China Cord Blood Bank (through contract manufacturing customer OriGen Biomedical), Community Blood Services and its numerous contract banking services customers, ViaCord, a cord blood banking service, and previously announced Lifeforce Cryobanks and New England Cord Blood Bank.

Mike Rice, Chairman and CEO, commented on BioLife's increasing share of this market by stating, "Through our direct sales channel, we've built a solid foundation of high-volume end-users of our GMP grade CryoStor and BloodStor® stem cell freeze media products. Over the last two years, we've also grown our market share through private label contract manufacturing agreements with leading suppliers of cord blood processing tools, whose customers include some of the world's largest cord blood banking organizations.  We estimate that through our direct and indirect distribution channels, we are the leading supplier of pre-formulated cord blood and tissue stem cell freeze media products."

BioLife management estimates that over 500,000 cord blood units were processed in 2010.

In support of the Company's objective to continually increase the quality profile of its proprietary, generic, and contract manufacturing products, BioLife is currently qualifying a GMP syringe filling line with a plan to offer sterile, single-use syringe packaging options for these products later in 2011.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer